Is ABUS a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Arbutus Biopharma (ABUS) rests on Imdusiran functional-cure program: Imdusiran, an RNAi therapeutic that suppresses HBV antigens, is Arbutus's lead asset and the core of the thesis. The bear case rests on arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatitis B virus (cHBV), a disease affecting hundreds of millions of people worldwide for which current treatments rarely cure. Its lead candidate is imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNAi (RNA interference) therapeutic designed to suppress all HBV antigens, including surface antigen (HBsAg), and it is being studied in combination regimens. Arbutus has reported that a number of patients across its Phase 2a IM-PROVE trials achieved a functional cure when imdusiran was combined with standard antivirals plus agents like pegylated interferon or low-dose immunotherapy, and in 2026 the FDA granted imdusiran Fast Track designation. A second candidate, AB-101, is an oral PD-L1 inhibitor in early clinical testing meant to reawaken the immune response against HBV. As a clinical-stage biotech, Arbutus has no meaningful product revenue and funds itself through its balance sheet, partnerships, and licensing. The defining recent event is a $2.25 billion global patent settlement with Moderna, reached with its licensee Genevant, resolving litigation over lipid-nanoparticle delivery technology used in COVID-19 vaccines. The structure includes a large noncontingent payment (of which Arbutus expects to receive a sizable share, reported as an estimated $178.7 million, arriving in mid-2026) plus a further contingent amount tied to an appellate ruling. This cash meaningfully extends Arbutus's runway and has prompted the company to evaluate potential shareholder distributions. The investment picture is therefore a blend of clinical-pipeline optionality and an unusually strong, litigation-driven cash position. Verify all trial-status, settlement, and cash figures against Arbutus's latest filings before acting.
The bull case for ABUS
1. Imdusiran functional-cure program
Imdusiran, an RNAi therapeutic that suppresses HBV antigens, is Arbutus's lead asset and the core of the thesis. The company has reported patients across its Phase 2a IM-PROVE trials achieving a functional cure in combination regimens, with several sustaining it for over two years, and the FDA granted Fast Track designation in 2026. Chronic hepatitis B is a large, underserved market where a true functional cure would be highly valuable, so imdusiran's continued clinical progress is the single biggest driver of long-term value.
2. Moderna settlement and cash
Arbutus and its licensee Genevant reached a $2.25 billion global settlement with Moderna over lipid-nanoparticle patent litigation. The structure includes a large upfront noncontingent payment plus a contingent amount tied to an appellate ruling, with Arbutus expecting to receive a sizable share in mid-2026. This influx dramatically strengthens a small biotech's balance sheet, extending runway to fund trials and even prompting the company to evaluate returning capital to shareholders.
3. Combination and pipeline breadth
Arbutus is pursuing a functional cure through combination therapy, pairing imdusiran with standard antivirals and agents like pegylated interferon or immunotherapeutics, and it has a second candidate, AB-101, an oral PD-L1 inhibitor meant to reawaken HBV-specific immunity. This multi-mechanism approach reflects the scientific consensus that curing chronic HBV likely requires combining several distinct mechanisms, and gives Arbutus more than one shot on goal.
4. Regulatory and partnering optionality
Fast Track designation for imdusiran can facilitate development and potentially speed FDA review, a meaningful signal for a small biotech. With a strengthened balance sheet, Arbutus has flexibility to advance trials independently or pursue partnerships and licensing. How the company deploys its settlement cash, whether toward accelerating the pipeline, business development, or shareholder distributions, is an important part of the forward story alongside the clinical data itself.
The bear case for ABUS
Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. Curing chronic hepatitis B is scientifically hard, and functional-cure results seen in small Phase 2a groups may not hold up in larger, later-stage trials, which would sharply reduce the stock's value. The candidates still face years of development, regulatory uncertainty, and competition from other companies pursuing HBV cures. The Moderna settlement, while transformative, has a large contingent portion tied to an appellate ruling that may not be received in full, and the value of the cash depends on how wisely management deploys it. Biotech stocks are volatile and can move sharply on single data readouts. Investors should treat ABUS as a high-risk, potentially high-reward position rather than a stable holding.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ABUS already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ABUS
Too few analysts publish on ABUS for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The ABUS forecast page covers what coverage does exist.
How is ABUS valued? (as of Jul 2026)
Snapshot for ABUS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Stage: Clinical-stage biotech; no meaningful product revenue
- Lead asset: Imdusiran (AB-729), RNAi for chronic hepatitis B, Phase 2a, FDA Fast Track
- Second asset: AB-101, oral PD-L1 inhibitor, early clinical
- Moderna settlement: $2.25B global settlement (noncontingent ~$950M plus ~$1.3B contingent); Arbutus expects ~$178.7M share in mid-2026 (verify live)
- Cash position: Reported around ~$95 million before settlement proceeds (as of an early-2026 quarter; confirm live)
- Profitability: Operating at a loss, typical of clinical-stage biotech; settlement revenue distorts recent reported results
These figures are approximate and tied to the Jul 2026 asOf date; verify live trial status, settlement terms and receipts, and cash figures against Arbutus's latest quarterly filings before acting. Traditional valuation multiples do not apply cleanly to a pre-revenue biotech: the stock is driven by clinical data, regulatory milestones, and, unusually here, the litigation settlement cash, so earnings snapshots are less meaningful than pipeline progress and balance-sheet strength.
How do you decide if ABUS is a buy?
Rather than asking whether ABUS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ABUS indirectly through an index or sector ETF before adding more.
What would change your mind on ABUS
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Imdusiran functional-cure program stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ABUS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ABUS against your real portfolio and see your actual exposure before deciding.
Investing in Arbutus Biopharma with AI
Connect the broker you already use and ask Walnut's AI how ABUS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ABUS a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Imdusiran functional-cure program, with stage at Clinical-stage biotech; no meaningful product revenue. The bear case rests on arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ABUS?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for ABUS?
+
Imdusiran functional-cure program. Imdusiran, an RNAi therapeutic that suppresses HBV antigens, is Arbutus's lead asset and the core of the thesis.
What is the bear case for ABUS?
+
Arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage. Curing chronic hepatitis B is scientifically hard, and functional-cure results seen in small Phase 2a groups may not hold up in larger, later-stage trials, which would sharply reduce the stock's value. The candidates still face years of development, regulatory uncertainty, and competition from other companies pursuing HBV cures. The Moderna settlement, while transformative, has a large contingent portion tied to an appellate ruling that may not be received in full, and the value of the cash depends on how wisely management deploys it. Biotech stocks are volatile and can move sharply on single data readouts. Investors should treat ABUS as a high-risk, potentially high-reward position rather than a stable holding.
What does Arbutus Biopharma do?
+
Arbutus Biopharma is a clinical-stage biopharmaceutical company that leverages deep virology expertise to develop novel therapeutics aimed at a functional cure for chronic hepatiti
What would have to change for ABUS to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Imdusiran functional-cure program) stalling in the reported numbers rather than in the narrative, the risk above (arbutus carries the full risk profile of a clinical-stage biotech: it is not profitable, has no approved product generating meaningful revenue, and its value depends on trial outcomes that can fail at any stage) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Is ABUS a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is promising imdusiran functional-cure data, FDA Fast Track designation, and an unusually strong cash position from the Moderna settlement. The bear case is the ordinary high risk of an unprofitable clinical-stage biotech whose value hinges on trial results that can fail, plus uncertainty over the contingent settlement portion. Treat it as high-risk and verify current figures first.
What does Arbutus Biopharma actually do?
+
Arbutus is a clinical-stage biotech developing therapies aimed at a functional cure for chronic hepatitis B. Its lead candidate, imdusiran, is an RNAi (RNA interference) drug that suppresses hepatitis B antigens, studied in combination with other agents. A second candidate, AB-101, is an oral PD-L1 inhibitor meant to reawaken the immune response against the virus. It has no approved products generating meaningful revenue yet.
What is the Moderna settlement about?
+
Arbutus and its licensee Genevant reached a $2.25 billion global settlement with Moderna resolving patent litigation over lipid-nanoparticle delivery technology used in COVID-19 vaccines. The structure includes a large upfront noncontingent payment plus a further amount contingent on an appellate ruling. Arbutus expects to receive a sizable share (reported around $178.7 million) in mid-2026, which materially strengthens its balance sheet.
Walnut is informational, not investment advice, and gives no verdict on ABUS. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.